Weather in Kaunas

Time in

Vilnius, Tallinn, Riga

www.ema.europa.eu

Syndicate content
Pending EC decisions and European Public Assessment Reports (EPARs): Human medicinal products
URL: http://www.ema.europa.eu
Updated: 9 hours 51 min ago

Human medicines European Public Assessment Report (EPAR): Prolia, denosumab, Revision: 2, Authorised

Wed, 05/16/2012 - 17:00
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Fablyn, lasofoxifene, Revision: 2, Authorised

Wed, 05/16/2012 - 16:50
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Circadin, melatonin, Revision: 14, Authorised

Wed, 05/16/2012 - 10:20
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Prometax, rivastigmine, Revision: 23, Authorised

Fri, 05/11/2012 - 16:16
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Prometax, rivastigmine, Revision: 23, Authorised

Fri, 05/11/2012 - 16:16
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Capecitabine Teva, capecitabine, Revision: 0, Authorised

Fri, 05/11/2012 - 16:12
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Capecitabine Teva, capecitabine, Revision: 0, Authorised

Fri, 05/11/2012 - 16:12
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Tandemact, pioglitazone / glimepiride, Revision: 8, Authorised

Fri, 05/11/2012 - 16:11
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Tandemact, pioglitazone / glimepiride, Revision: 8, Authorised

Fri, 05/11/2012 - 16:11
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Temozolomide Sandoz, temozolomide, Revision: 4, Authorised

Fri, 05/11/2012 - 11:00
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Halaven , eribulin, Revision: 1, Authorised

Thu, 05/10/2012 - 17:30
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Exelon, rivastigmine, Revision: 25, Authorised

Thu, 05/10/2012 - 11:00
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Tysabri, natalizumab, Revision: 13, Authorised

Tue, 05/08/2012 - 17:15
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Tysabri, natalizumab, Revision: 13, Authorised

Tue, 05/08/2012 - 17:15
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Dexdor, dexmedetomidine, Revision: 1, Authorised

Tue, 05/08/2012 - 17:00
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Dexdor, dexmedetomidine, Revision: 1, Authorised

Tue, 05/08/2012 - 17:00
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Zalasta, olanzapine, Revision: 9, Authorised

Tue, 05/08/2012 - 16:55
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Zalasta, olanzapine, Revision: 9, Authorised

Tue, 05/08/2012 - 16:55
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Sancuso, granisetron, Revision: 0, Authorised

Tue, 05/08/2012 - 12:34
Categories: Category 1

Human medicines European Public Assessment Report (EPAR): Sancuso, granisetron, Revision: 0, Authorised

Tue, 05/08/2012 - 12:34
Categories: Category 1
  • Profesionalumas.
    Esame savo srities specialistai ir mėgstame savo darbą, todėl darbų kokybę garantuojame.
  • Konkurencingumas.
    Poreikius atitinkantys sprendimai už konkurencingą kainą.
  • Konfidencialumas.
    Vertiname bendradarbiavimą, išlaikome konfidencialumą, siekiame tapti ilgalaikiu partneriu.
 

My status

Priklausome